GSK extends pneumococcal vaccine agreement with GAVI Alliance

Abstract:

GSK today announced it has expanded its agreement with the GAVI Alliance in a move to help protect millions more children in the world‟ s poorest countries from pneumococcal disease. Pneumococcal disease can lead to pneumonia, meningitis and sepsis and is a leading cause of death in children under the age of five in developing countries. Under this new agreement, GSK commits to provide an additional 180 million doses of its pneumococcal vaccine, Synflorix, to GAVI over the next 12 years to help expand immunisation programmes against pneumococcal disease to 72 developing countries by 2023.

Año de publicación:

Keywords:

Fuente:

google